Serena Williams Faces Backlash for Weight-Loss Drug Endorsement
Tennis legend Serena William's recent endorsement of a weight-loss drug has sparked controversy. Williams, known for her 23 Grand Slam titles, publicly credited GLP-1 medication with helping her lose 14 kilos after two pregnancies.
This endorsement, however, has drawn criticism. Concerns centre on the potential for normalising the use of powerful obesity drugs among those who may not medically require them.
Critics argue that, as a global fitness icon, Williams actions send a potentially harmful message about body image, particularly to young fans. Medical professionals have emphasised the significant side effects of GLP-1 agonists, such as Ozempic and Wegovy, including pancreatitis, blindness, and kidney damage.
They stress the importance of using these medications only under strict medical supervision. The debate highlights the complex issue of celebrity endorsements and their impact on public health.